ALTASCIENCES
Altasciences recently completed an important First-in-Human (FIH), Phase I, integrated adaptive clinical trial, including single and multiple ascending doses (SAD and MAD), Project Management, Bioanalysis, and Medical Writing, for sponsor Bellus Health.
Altasciences’ contributions to the positive top-line results were significant. From recruitment of 90 subjects to management of all relevant aspects of this important FIH trial, Altasciences used a flexible and adaptive approach to fully meet the client’s needs. Altasciences’ contributions allowed Bellus Health to make a well-informed decision to proceed with their promising drug candidate for chronic cough.
“We awarded this trial to Altasciences based on their reputation for quality, speed and efficiency, and we were not disappointed. Thanks to their great efforts, we have been able to determine that our compound is safe and well-tolerated, and we are proceeding to the next stage of development without delay. Altasciences’ ability to deliver results efficiently helped us make important decisions to move ahead ,” says Dr. Denis Garceau, Senior Vice President, Drug Development, at Bellus Health.
Altasciences conducts hundreds of early phase clinical trials annually. Their vast participant database permits rapid recruitment, and they are constantly refining their processes and offerings to better meet sponsor needs.
“We are very proud of our work on novel compounds at Altasciences, and the fact that we’re able to deliver results in a timely, efficient manner that meets or exceeds our sponsors’ drug development timelines, ” says Ingrid Holmes, Vice President, Global Clinical Operations, for Altasciences.
About Altasciences
Altasciences is a mid-size contract research organization with a unique focus on supporting drug development from lead candidate selection to proof of concept. Altasciences encompasses Algorithme Pharma in Montreal, QC, Vince & Associates Clinical Research in Kansas City, KS, Algorithme Pharma USA in Fargo, ND, and Altasciences Preclinical Services in Seattle, WA. With over 25 years of industry experience, Altasciences provides preclinical and clinical solutions to an international customer base of biopharmaceutical companies. Altasciences’ full-service solutions offering in this critical stage of drug development includes preclinical safety testing, clinical pharmacology services, bioanalysis, medical writing, biostatistics, data management, and overall program management.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181212005420/en/
Contact:
Julie-Ann Cabana jcabana@altasciences.com 913 304-4505
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Global styrker platformen i Filippinerne med Du-Baladad and Associates3.5.2025 00:55:00 CEST | Pressemeddelelse
Andersen Global forstærker sit engagement i Asien og Stillehavsområdet gennem en samarbejdsaftale med Du-Baladad and Associates, et skatte- og virksomhedsservicefirma med base i Filippinerne. Firmaet blev grundlagt i 2009 af administrerende partner Benedicta Du-Baladad og tilbyder en bred vifte af ydelser, herunder skatterådgivning og -planlægning, transfer pricing, international skat, skattetvister og -retssager, compliance og bistand i forbindelse med incitamenter. Du-Baladad and Associates anerkendes konsekvent som et førende skattefirma i Filippinerne af Chambers and Partners, International Tax Review, The Legal 500 og Asialaw og servicerer multinationale virksomheder og store indenlandske selskaber på tværs af brancher, herunder inden for finansielle tjenesteydelser, energi, olie og gas, produktion, fast ejendom og teknologi. "Vores firma bygger på en helhedsorienteret tilgang til kunderne, som prioriterer praktiske og skræddersyede strategier til at styre risici og understøtte vo
Spatial Releases 2025 1.0.1 with Enhancements for CAD Translation, Model Simplification, and Mesh Preparation for Manufacturing and Simulation2.5.2025 16:47:00 CEST | Press release
Spatial Corp., the leading software development toolkit provider for design, manufacturing and engineering solutions and a subsidiary of Dassault Systèmes, announces the 2025 1.0.1 release and updates across several product lines, reaffirming its commitment to providing innovative solutions for its customers in domains ranging from CAD to simulation, manufacturing, and beyond. The 2025 1.0.1 release delivers expanded functionality designed to streamline manufacturing and simulation workflows. Key highlights include a new custom feature detection API in ACIS for more efficient model simplification, expanded CAD format support—including STEP AP242 PMI writing—and continued enhancements to hidden-body removal. With this release, Spatial reduces manual tasks, increases fidelity in geometry translation, and strengthens its toolset for automated design-to-manufacture and design-to-simulation pipelines. 3D ACIS ModelerCustom Feature Detection (Beta): Model simplification often requires manual
Decent Cybersecurity Joins the Council of Slovak Exporters to Strengthen European Cybersecurity Exports2.5.2025 15:51:00 CEST | Press release
Decent Cybersecurity, a leading European provider of post-quantum security solutions, announces its membership in the Council of Slovak Exporters (CSE), reinforcing its commitment to expanding advanced cybersecurity exports across global markets. This strategic partnership combines Decent Cybersecurity's expertise in critical infrastructure protection with CSE's established export promotion platform. As a company holding national, EU, and NATO "Secret" level security clearances, Decent Cybersecurity brings specialized knowledge in post-quantum security, blockchain technology, and space traffic management solutions to the Council's network. "Joining the Council of Slovak Exporters represents a significant opportunity to strengthen Slovakia's position in the global cybersecurity market," said Matej Michalko, Founder and CEO of Decent Cybersecurity and a long-term expert on post-quantum cryptography and blockchain. "As cyber threats continue to evolve, our advanced solutions are increasin
Saudi Arabia Hosts EDGEx 2025, Pushing the Boundaries of Education2.5.2025 15:29:00 CEST | Press release
Saudi Arabia has taken another step forward in its educational reform journey with the successful conclusion of the International Education Exhibition (EDGEx), held from April 13–16, 2025. Organized by the Ministry of Education, the event convened education leaders, technology developers, and policymakers from around the world under the theme “Beyond Readiness.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250502190798/en/ Saudi Arabia Hosts EDGEx 2025, Pushing the Boundaries of Education (Photo: AETOSWire) Over four days, EDGEx welcomed more than 20,000 local and international visitors, including government representatives, senior educators, academics, business leaders, and professionals in the field. The exhibition served as a platform for dialogue, knowledge exchange, and cross-sector collaboration—bringing together institutions, companies, and decision-makers to explore how education and training can evolve in a rapidl
IFF Announces Tender Offers for Certain Outstanding Series of Notes2.5.2025 15:10:00 CEST | Press release
IFF (NYSE: IFF) announced today the commencement of tender offers to purchase for cash certain of its outstanding series of notes listed in the tables below (collectively, the “Notes”) for an aggregate purchase price, excluding accrued and unpaid interest, of up to $1.8 billion. Pool 1 Tender Offers Pool 1 Maximum Amount: $1.0 billion(1(a)) Title of Security CUSIP/ISIN Principal Amount Outstanding(in millions) Acceptance Priority Level(2) Series Tender Cap(3) U.S. Treasury Reference Security Bloomberg Reference Page Fixed Spread(4) Early Tender Payment (4)(5) 1.230% Senior Notes due 2025 459506AN1 U45950AE9 $1,000 1 $500 million 5.000% UST due 9/30/25 FIT3 + 0 bps $30 1.832% Senior Notes due 2027 459506AP6 U45950AF6 $1,200 2 $300 million 3.750% UST due 4/30/27 FIT1 + 75 bps $30 2.300% Senior Notes due 2030 459506AQ4 U45950AG4 $1,500 3 N/A 3.875% UST due 4/30/30 FIT1 + 110 bps $30 4.450% Senior Notes due 2028 459506AK7 US459506AK78 $400 4 N/A 3.750% UST due 4/15/28 FIT1 + 95 bps $30 Poo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom